MSB has always had risk associated with it due to the costs involved in running multiple trials in a number of key disease states.
At this stage we have 1 study which is the smallest of the addressable disease states, being asked by the FDA for a further study. We can argue that all of the evidence thus far and the 9-1 ODAC ruling should’ve been enough, however it wasn’t and they need a more rigorous trial which will happen in adults.
The key to MSB is the upcoming results for COVID, heart and back pain. These results will be off the back of rigorous studies and if you BELIEVE the science then we expect positive results and ultimately a favourable FDA outcome as this will be irrefutable.
IMO by the end of November there will be no need for ramping one way or the other as you will have all the information you need to either HOTDL or walk away!
GLTAH
MSB has always had risk associated with it due to the costs...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.020(1.91%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.07 | $1.04 | $4.010M | 3.797M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 67587 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 45960 | 7 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.07 |
Change
0.020 ( 2.55 %) |
||||
| Open | High | Low | Volume | ||
| $1.04 | $1.07 | $1.04 | 699949 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| MSB (ASX) Chart |